This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Ember Therapeutics, Inc.

Drug Names(s): BMP-7/OP-1, OP-1, Osteogenic Protein-1, rhBMP-7/OP-1

Description: BMP-7 is an inhibitor of BMP-7, a member of the TGF-beta protein. Bone morphogenetic protein familiy members play key roles in the transformation of mesenchymal cells into bone and cartilage.

Deal Structure: Curis and Johnson & Johnson
In November 2002, Curis announced that the BMP-7 for the treatment of various kidney and neurological related disorders, was licensed to Ortho Biotech Products (a Johnson & Johnson subsidiary).

Curis and Stryker
In December 2007, Curis will receive an initial payment of $1 million, which is net of a payment to be made by Curis to a former third party collaborator of Creative BioMolecules, a predecessor company involved in the 2000 merger that formed Curis. In addition to the initial payment, Stryker has agreed to make cash payments to Curis upon the successful achievement of specified clinical development and drug approval objectives. In lieu of royalty payments, Stryker has also agreed to pay additional cash payments upon the achievement of specified net product sales targets, should such targets be achieved within contractually-specified time periods that are based on the expiration of valid claims of Curis' BMP-7...See full deal structure in Biomedtracker

Partners: Johnson & Johnson Knight Therapeutics Inc.

BMP-7 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug